Molecular biological foundation of targeted therapy for metastatic renal cell carcinoma.
- Author:
Chong LAI
1
;
Xiaodong TENG
2
Author Information
1. Department of Urology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
2. Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Carcinoma, Renal Cell;
drug therapy;
Humans;
Kidney Neoplasms;
drug therapy;
Molecular Targeted Therapy;
Neoplasm Metastasis;
Von Hippel-Lindau Tumor Suppressor Protein;
metabolism
- From:
Journal of Zhejiang University. Medical sciences
2016;45(1):91-97
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of renal cell carcinoma (RCC) is increasing. Radical cure by surgery can only be achieved in patients with early stage tumors. How to precisely use antineoplastic agents after surgery is an important problem to be solved. Most metastatic RCCs are pathologically identified as clear cell RCC (ccRCC), thus to develop agents targeting ccRCC is critical. Most clinically available targeted therapies are based on targeting some spots in specific pathways; or based on targeting new anti-tumor mechanisms, such as programmed death-1(PD-1), antibody-drug conjugates (ADC) and stem cells. There is still no targeted therapy having definite effect to most RCC patients. Only von Hippel-Lindau (VHL) pathway so far has been confirmed to be related to ccRCC development and progression; the inactivation of VHL gene causes many significant downstream gene changes. The key proteins involved in VHL pathway may be potential therapeutic targets for ccRCC. In this article, we review the current progress of targeted therapy for RCC, focus on the molecular characteristics of ccRCC, its relation to VHL pathway, the potential therapeutic targets and future clinical application for metastatic ccRCC.
